

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,200	07/11/2001	Christopher S. Chen	56252	1223
21874	7590 06/28/2005		EXAMINER	
EDWARDS	& ANGELL, LLP		NAFF, D.	AVID M
P.O. BOX 558 BOSTON, M	• •		ART UNIT	PAPER NUMBER
· · · ·			1651	

DATE MAILED: 06/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)				
	09/904,200	CHEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	David M. Naff	1651				
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a release of the maximum statutory perions for reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no event, however, may a reply be tireply within the statutory minimum of thirty (30) day do will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 13	April 2005.					
,— ·—	nis action is non-final.					
3) Since this application is in condition for allow						
Disposition of Claims						
4) ☐ Claim(s) 64-68,70-80 and 83-95 is/are pendidate 4a) Of the above claim(s) is/are withdensity is/are withdensity is/are allowed. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 64-68, 70-80 and 83-95 is/are reject 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and	rawn from consideration.					
Application Papers	·					
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a life.	ents have been received. ents have been received in Applicat riority documents have been receiv eau (PCT Rule 17.2(a)).	ion No ed in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 	Paper No(s)/Mail D	Pate Patent Application (PTO-152)				
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	6) Other:					

H

Art Unit: 1651

DETAILED ACTION

An amendment of 4/13/05 amended claim 64, canceled claims 81 and 82, and added new claims 93-95.

Claims examined on the merits are 64-68, 70-80 and 83-95; which are all claims in the application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 103

Claims 64-68, 70-80 and 83-95 are rejected under 35 U.S.C. 103(a) as being unpatentable over Singhvi et al (6,368,838 B1) in view of Dewez et al (WO 96/15223) and Anderson et al (6,686,184 B1) for reasons in the previous office action of 12/14/05 and for reasons herein.

The claims are drawn to a device containing a substrate having thereon a plurality of cytophilic regions that can adhere biomolecules and cytophobic regions to which the biomolecules do not adhere, and the cytophobic regions contain a surfactant compound. The substrate comprises a polymeric surface and the surface may comprises microfluidic channels.

Singhvi et al disclose a device having cytophilic islands for adhering cells and cytophobic regions which isolate the cytophilic islands. The cytophilic islands may contain extracellular matrix proteins (col 9, lines 32-33) to promote binding of cells (col 9, lines 22-26).

Art Unit: 1651

Dewez et al disclose a biomaterial for selective adhesion of cells or tissue which contains a polymeric support having a heterogeneous surface conditioned with a surfactant and an extracellular matrix protein. The extracellular matrix protein adheres to one surface area of the support and the surfactant adheres to another surface area where it inhibits adsorption of the extracellular matrix protein (paragraph bridging pages 3 and 4). Cells preferentially adhere to the portion of the support containing the extracellular matrix protein (page 4, lines 12-16).

Anderson et al disclose patterning surfaces using a stamp containing microfluidic channels.

It would have been obvious to provide the cytophilic islands of the device of Singhvi et al with extracellular matrix protein to enhance the binding of cells as suggested by Singhvi et al and Dewez et al, and it would have been obvious to provide the cytophobic regions of Singhvi et al with a surfactant to inhibit binding of extracellular matrix protein to these regions as suggested by Dewez et al. It would have further been obvious to provide the device of Singhvi et al with microfluidic channels to obtain the function of these channels in patterning a surface as disclosed by Anderson et al since the device of Singhvi et al can be used for patterning a surface as shown by Figure 1. The conditions of dependent claims would have been matters of obvious choice within the skill of the art in view of

Art Unit: 1651

the disclosures of the references. The surfactant of Dewez et al can be a polyethylene oxide (page 19, 5). Selecting another known surfactant that provides the same function would have been obvious. The devices of Singhvi et al and Dewez et al can have various forms and shapes and to provide channels as claimed by claims 81 and 82 would have been obvious. As to claims 91 and 92, the surface of Singhvi et al can be made of plastic or polysulfone compounds (col 8, lines 44-45). Polysulfones are hydrophobic. Selecting other polymers that provide the same function would have been obvious.

Response to Arguments

Applicant's arguments filed 4/13/05 have been fully considered but they are not persuasive.

Applicants arguments are of the type previously submitted, and the response below is that previously presented to these arguments.

Applicants urge that in Singhvi et al cytophobic regions are created by SAMs, and does not suggest the use of a surfactant to create a cytophobic region. However, it would have been obvious to adsorb a surfactant on a cytophobic SAM in a similar way that Dewez et al adsorb a surfactant on a hydrophobic surface. Moreover, it would have been obvious to use a surfactant to form a cytophobic SAM since Dewez et al

Art Unit: 1651

disclose (page 5, lines 16-19) that the surfactant can contain a polyethylene oxide group and Singhvi et al disclose that a biophobic SAM can contain a polyethylene glycol group (col 9, line 60).

Applicants urge that Dewez et al use plasma treatment and do not disclose using a surfactant with an untreated surface. However, the surfactant would have been expected to absorb to other surfaces, and groups disclosed by Singhvi et al (col 9) for a SAM forming compound would have been expected to adsorb a surfactant.

Applicants urge that a metal surface is required for SAMS. However, this is not supported by evidence. It appears a polymeric surface can be treated to be functional with SAMS.

As to the microfluidic channels of claim 93-95, these are suggested by Anderson et al.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened

Application/Control Number: 09/904,200 Page 6

Art Unit: 1651

statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is 571-272-0920. The examiner can normally be reached on Monday-Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 751-273-8300.

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David M. Naff Primary Examiner Art Unit 1651 Page 7

DMN 6/27/05